Our Pricing

Private Wegovy or Ozempic Prescription - No GP Referral

Published on: June 03, 2026

Accessing a private Wegovy or Ozempic prescription UK service has become increasingly straightforward for patients seeking clinically proven weight loss support. At Cured Pharmacy, our UK-registered prescribers conduct comprehensive online consultations in under three minutes, assessing your suitability for semaglutide-based treatments without requiring a GP referral. Both medications are MHRA-licensed, dispensed by our GPhC-registered pharmacy, and delivered discreetly to your door.

Understanding Wegovy and Ozempic: Same Active Ingredient, Different Purposes

Both Wegovy and Ozempic contain semaglutide, a GLP-1 receptor agonist that mimics a naturally occurring hormone involved in appetite regulation and glucose metabolism [1]. The key distinction lies in their licensed indications and dosing schedules: Ozempic was originally developed for type 2 diabetes management at doses up to 1mg weekly, whilst Wegovy is specifically licensed for chronic weight management at higher doses up to 2.4mg weekly [2].

In the landmark STEP 1 trial, participants using Wegovy 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. This represented the most significant weight loss outcome from any pharmaceutical intervention at the time of publication. Ozempic, when prescribed off-label for weight management at its maximum 1mg dose, typically produces more modest reductions of approximately 10-12% [3].

The pharmacological mechanism centres on slowing gastric emptying, reducing appetite signals to the brain, and enhancing insulin secretion in response to meals [1]. Patients commonly report feeling fuller sooner during meals and experiencing fewer cravings between eating occasions. These effects develop gradually over the first 4-8 weeks as the dose is titrated upward according to your prescriber's protocol.

Private Wegovy or Ozempic Prescription UK: How the Process Works

Obtaining a private prescription through Cured Pharmacy begins with a structured clinical questionnaire that gathers your medical history, current medications, weight management goals, and any contraindications. Our UK-registered prescribers review each submission individually—this is not an automated approval system. You'll receive a decision typically within 24 hours, and if approved, your prescription is sent electronically to our dispensing team.

The assessment evaluates your body mass index (BMI), previous weight loss attempts, co-existing health conditions such as cardiovascular disease or sleep apnoea, and any medications that might interact with semaglutide [4]. For Wegovy, NICE guidelines recommend prescription for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity [5]. Our prescribers follow these evidence-based thresholds whilst considering individual circumstances.

Once dispensed, your medication is packaged discreetly with no external markings indicating contents, and shipped via tracked courier. Each pen arrives with comprehensive patient information leaflets, injection technique guidance, and details for ongoing prescriber support. Follow-up consultations are conducted at 4-week intervals initially to monitor progress, adjust dosing, and address any side effects.

What to Expect During Your Online Consultation

The consultation questionnaire covers essential clinical parameters: your current weight and height, any history of pancreatitis or thyroid conditions, medications including over-the-counter supplements, and your realistic weight loss targets. Prescribers pay particular attention to contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, both of which preclude semaglutide use [1]. The entire process is designed to replicate the thoroughness of an in-person GP consultation whilst offering greater convenience and faster access to treatment.

Wegovy vs Ozempic for Weight Loss: Clinical Outcomes and Practical Differences

When comparing these medications head-to-head, Wegovy's higher maximum dose of 2.4mg provides superior weight loss outcomes in clinical trials. The STEP programme demonstrated consistent advantages across diverse patient populations, including those with pre-existing type 2 diabetes and cardiovascular risk factors [2]. Ozempic, whilst highly effective for glycaemic control, was not studied at weight-focused doses in its pivotal trials, though real-world evidence suggests comparable efficacy when prescribed off-label at 1mg weekly.

From a practical standpoint, Wegovy pens are colour-coded by dose strength and designed with a simplified injection mechanism that many patients find intuitive. The titration schedule typically begins at 0.25mg weekly, increasing every four weeks until reaching the maintenance dose of 2.4mg. Ozempic follows a similar escalation pattern but caps at 1mg, which may be sufficient for patients with more modest weight loss goals or those experiencing dose-limiting side effects at higher strengths [3].

Cost considerations also factor into treatment choice. Wegovy is priced from £79.00 at Cured Pharmacy, reflecting competitive UK market positioning for the licensed weight management formulation. Both medications require ongoing monthly prescriptions to maintain therapeutic effect, and weight regain is common if treatment is discontinued without implementing sustainable lifestyle modifications [6].

Which Medication Suits Your Circumstances?

Your prescriber will recommend the most appropriate option based on your weight loss targets, medical history, and response to initial dosing. Patients seeking maximum weight reduction typically benefit from Wegovy's higher-dose protocol, whilst those with concurrent type 2 diabetes may find Ozempic addresses both conditions effectively. Neither medication is inherently superior—the optimal choice depends on individual clinical context and treatment priorities.

Alternative GLP-1 Treatments: Mounjaro, Saxenda, and Emerging Options

Beyond semaglutide-based treatments, the UK market now includes tirzepatide (Mounjaro), which acts on both GLP-1 and GIP receptors to produce even greater weight loss in head-to-head trials [7]. The SURPASS-2 study demonstrated that tirzepatide 15mg weekly resulted in 12.4kg greater weight reduction compared to semaglutide 1mg over 40 weeks [7]. This dual-agonist mechanism represents the current frontier in pharmacological weight management, though it comes at a higher price point reflecting its novelty and enhanced efficacy.

Saxenda (liraglutide) offers a daily injection alternative for patients who prefer more frequent, lower-dose administration. Whilst requiring daily commitment, some individuals find the routine easier to maintain, and the lower per-injection dose may produce fewer gastrointestinal side effects during the initial titration phase [8]. Clinical trials showed average weight loss of 8-9% with Saxenda, positioning it between oral medications like orlistat and the more potent weekly GLP-1 agonists.

Our clinical team at Cured Pharmacy can discuss the full spectrum of licensed weight loss treatments during your consultation. Superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures all dispensed medications meet MHRA standards and originate from licensed UK wholesalers. This guarantees you receive genuine pharmaceutical products rather than counterfeit or grey-market alternatives that proliferate through unregulated online channels.

Managing Side Effects and Optimising Treatment Outcomes

Gastrointestinal side effects—particularly nausea, diarrhoea, and constipation—affect approximately 40-50% of patients initiating semaglutide therapy [2]. These symptoms typically peak during dose escalation phases and diminish as your body adapts to each new strength. Practical management strategies include eating smaller, more frequent meals, avoiding high-fat foods that delay gastric emptying further, and staying well-hydrated throughout the day.

Rare but serious adverse effects require immediate medical attention. These include persistent severe abdominal pain potentially indicating pancreatitis, visual changes, or signs of thyroid nodules such as a lump in the neck or difficulty swallowing [1]. Your prescriber will review warning signs during the initial consultation and provide clear guidance on when to seek urgent care versus routine follow-up.

Maximising weight loss outcomes requires combining medication with sustainable lifestyle modifications. Clinical trial participants who achieved the greatest reductions typically engaged in structured dietary counselling and increased physical activity alongside pharmacotherapy [6]. The medication provides a physiological advantage by reducing hunger and enhancing satiety, but long-term success depends on establishing healthier eating patterns and movement habits that persist beyond the treatment period.

When to Contact Your Prescriber

Reach out to our clinical team if you experience side effects that interfere with daily functioning, if you're not seeing expected weight loss after 12-16 weeks at the maintenance dose, or if your circumstances change (new medications, pregnancy, planned surgery). We offer unlimited messaging support throughout your treatment journey, ensuring you never feel unsupported between formal consultation intervals.

Pricing, Supply, and Ongoing Treatment Considerations

Transparent pricing remains a cornerstone of our service model at Cured Pharmacy. Wegovy is available from £79.00 per pen, with the exact cost determined by your prescribed dose strength. We display all prices before you complete the consultation, eliminating surprise charges at checkout. This upfront approach contrasts with some services that only reveal costs after lengthy questionnaires, wasting your time if the price exceeds your budget.

UK supply of GLP-1 medications has experienced periodic constraints due to unprecedented global demand. We maintain relationships with multiple licensed wholesalers to maximise availability, and our pharmacy team proactively communicates any supply issues affecting your prescription. In cases of temporary shortage, we can discuss alternative treatments or adjust your dosing schedule in consultation with your prescriber to bridge supply gaps safely.

Long-term treatment duration varies by individual. Clinical guidelines suggest continuing therapy as long as you're achieving meaningful weight loss (defined as at least 5% reduction after 12-16 weeks) and tolerating the medication without significant adverse effects [5]. Many patients remain on treatment for 12-24 months before attempting a maintenance phase with reduced frequency or transitioning to lifestyle management alone. Your prescriber will review progress at regular intervals and adjust the treatment plan according to your evolving needs and goals.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. https://products.mhra.gov.uk/ [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in Endocrinology, 12, 645563. https://doi.org/10.3389/fendo.2021.645563 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
7. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
8. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment and lifestyle modifications.